Context: The pregnancy-associated plasma protein A2 (PAPP-A2) cleaves insulinlike growth factor binding proteins 3 and 5, releasing free insulinlike growth factor 1 (IGF-1). Homozygous mutations in PAPP-A2 result in growth failure with elevated total but low free IGF-1. Objective: To determine the 24-hour pharmacokinetic (PK) profile of free and total IGF-1 after a dose of recombinant human insulinlike growth factor 1 (rhIGF-1). We describe the growth response and effects on glucose metabolism and bone mineral density (BMD) after 1 year of rhIGF-1 therapy. Design and Patients: Three affected siblings, their heterozygous parents, and two healthy controls participated. The subjects received a dose of rhIGF-1, followed by serial blood samples collected over 24 hours. The two younger siblings were started on rhIGF-1 treatment. An oral glucose tolerance test and dual-energy X-ray absorptiometry scans were obtained at baseline and after 1 year of treatment. Results: Subcutaneous administration of rhIGF-1 increased the concentration of free and total IGF-1 in patients with PAPP-A2 deficiency. The PK profile was comparable in all participants. At baseline, all three subjects demonstrated insulin resistance and below-average BMD. Treatment with rhIGF-1 is ongoing in the youngest patient but was discontinued in his brother because of the development of pseudotumor cerebri. The treated patient had an increase in height velocity from 3.0 to 6.2 cm/y, resolution of insulin resistance, and an increase in total body BMD. Conclusions: rhIGF-1 at standard dosages resulted in similar PK characteristics in patients with PAPP-A2 deficiency, heterozygous relatives, and healthy controls. The youngest affected patient experienced a modest growth response to therapy with rhIGF-1, as well as beneficial effects on glucose metabolism and bone mass.
Context: The pregnancy-associated plasma protein A2 (PAPP-A2) cleaves insulinlike growth factor binding proteins 3 and 5, releasing free insulinlike growth factor 1 (IGF-1). Homozygous mutations in PAPP-A2 result in growth failure with elevated total but low free IGF-1. Objective: To determine the 24-hour pharmacokinetic (PK) profile of free and total IGF-1 after a dose of recombinant humaninsulinlike growth factor 1 (rhIGF-1). We describe the growth response and effects on glucose metabolism and bone mineral density (BMD) after 1 year of rhIGF-1 therapy. Design and Patients: Three affected siblings, their heterozygous parents, and two healthy controls participated. The subjects received a dose of rhIGF-1, followed by serial blood samples collected over 24 hours. The two younger siblings were started on rhIGF-1 treatment. An oral glucose tolerance test and dual-energy X-ray absorptiometry scans were obtained at baseline and after 1 year of treatment. Results: Subcutaneous administration of rhIGF-1 increased the concentration of free and total IGF-1 in patients with PAPP-A2 deficiency. The PK profile was comparable in all participants. At baseline, all three subjects demonstrated insulin resistance and below-average BMD. Treatment with rhIGF-1 is ongoing in the youngest patient but was discontinued in his brother because of the development of pseudotumor cerebri. The treated patient had an increase in height velocity from 3.0 to 6.2 cm/y, resolution of insulin resistance, and an increase in total body BMD. Conclusions: rhIGF-1 at standard dosages resulted in similar PK characteristics in patients with PAPP-A2 deficiency, heterozygous relatives, and healthy controls. The youngest affected patient experienced a modest growth response to therapy with rhIGF-1, as well as beneficial effects on glucose metabolism and bone mass.
Authors: Kasper Kjaer-Sorensen; Ditte H Engholm; Malene R Jepsen; Maria G Morch; Kathrin Weyer; Louise L Hefting; Louise L Skov; Lisbeth S Laursen; Claus Oxvig Journal: J Cell Sci Date: 2014-09-18 Impact factor: 5.285
Authors: L Hyldstrup; G S Conway; K Racz; A Keller; P Chanson; M Zacharin; A L Lysgaard; A H Andreasen; A-M Kappelgaard Journal: Osteoporos Int Date: 2011-11-29 Impact factor: 4.507
Authors: Nele Friedrich; Ole D Wolthers; Ayman M Arafat; Rebecca T Emeny; Joachim Spranger; Josefine Roswall; Jürgen Kratzsch; Hans J Grabe; Christoph Hübener; Andreas F H Pfeiffer; Angela Döring; Maximilian Bielohuby; Jovanna Dahlgren; Jan Frystyk; Henri Wallaschofski; Martin Bidlingmaier Journal: J Clin Endocrinol Metab Date: 2014-01-31 Impact factor: 5.958
Authors: N A Sims; P Clément-Lacroix; F Da Ponte; Y Bouali; N Binart; R Moriggl; V Goffin; K Coschigano; M Gaillard-Kelly; J Kopchick; R Baron; P A Kelly Journal: J Clin Invest Date: 2000-11 Impact factor: 14.808
Authors: Wolfgang Högler; David D Martin; Nicola Crabtree; Peter Nightingale; Jeremy Tomlinson; Lou Metherell; Ron Rosenfeld; Vivian Hwa; Stephen Rose; Joanna Walker; Nicholas Shaw; Timothy Barrett; Jan Frystyk Journal: J Clin Endocrinol Metab Date: 2014-01-13 Impact factor: 5.958
Authors: Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa Journal: Endocr Rev Date: 2019-04-01 Impact factor: 19.871
Authors: Masanobu Fujimoto; Jane C Khoury; Philip R Khoury; Bhanu Kalra; Ajay Kumar; Patrick Sluss; Claus Oxvig; Vivian Hwa; Andrew Dauber Journal: Eur J Endocrinol Date: 2020-03 Impact factor: 6.664
Authors: Aesha Shah; William C Dodson; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Carol L Gnatuk; Stephanie J Estes; Kelly C Allison; David B Sarwer; Patrick M Sluss; Christos Coutifaris; Anuja Dokras; Richard S Legro Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958